Louisiana State Employees Retirement System Sells 300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Louisiana State Employees Retirement System cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,300 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Louisiana State Employees Retirement System’s holdings in Regeneron Pharmaceuticals were worth $15,033,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of REGN. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at $28,000. Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $33,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $33,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 0.4 %

Shares of Regeneron Pharmaceuticals stock opened at $933.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The business has a 50-day moving average of $1,093.37 and a two-hundred day moving average of $1,039.90. The company has a market capitalization of $102.86 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the company earned $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on REGN shares. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Barclays reduced their price objective on Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating on the stock in a research note on Wednesday. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,101.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.